Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus

ABSTRACT Ebola virus causes outbreaks of severe viral hemorrhagic fever with high mortality in humans. The virus is highly contagious and can be transmitted by contact and by the aerosol route. These features make Ebola virus a potential weapon for bioterrorism and biological warfare. Therefore, a vaccine that induces both systemic and local immune responses in the respiratory tract would be highly beneficial. We evaluated a common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector against Ebola virus. HPIV3 recombinants expressing the Ebola virus (Zaire species) surface glycoprotein (GP) alone or in combination with the nucleocapsid protein NP or with the cytokine adjuvant granulocyte-macrophage colony-stimulating factor were administered by the respiratory route to rhesus monkeys—in which HPIV3 infection is mild and asymptomatic—and were evaluated for immunogenicity and protective efficacy against a highly lethal intraperitoneal challenge with Ebola virus. A single immunization with any construct expressing GP was moderately immunogenic against Ebola virus and protected 88% of the animals against severe hemorrhagic fever and death caused by Ebola virus. Two doses were highly immunogenic, and all of the animals survived challenge and were free of signs of disease and of detectable Ebola virus challenge virus. These data illustrate the feasibility of immunization via the respiratory tract against the hemorrhagic fever caused by Ebola virus. To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model.

[1]  G. Nolan,et al.  The ERK Mitogen-Activated Protein Kinase Pathway Contributes to Ebola Virus Glycoprotein-Induced Cytotoxicity , 2006, Journal of Virology.

[2]  B. Murphy,et al.  Nonsegmented Negative-Strand Viruses as Vaccine Vectors , 2006, Journal of Virology.

[3]  R. Koup,et al.  A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial , 2006, Clinical and Vaccine Immunology.

[4]  R. Koup,et al.  Competing Interests: GJN: , 2022 .

[5]  B. Murphy,et al.  A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs against a Lethal-Dose Ebola Virus Challenge , 2006, Journal of Virology.

[6]  J. Gonzalez,et al.  Fruit bats as reservoirs of Ebola virus , 2005, Nature.

[7]  R. V. van Lier,et al.  Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung , 2005, The Journal of experimental medicine.

[8]  M. St. Claire,et al.  Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates , 2005, Journal of Virology.

[9]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[10]  P. Collins,et al.  Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium , 2005, Journal of Virology.

[11]  Peter B Jahrling,et al.  Exotic emerging viral diseases: progress and challenges , 2004, Nature Medicine.

[12]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[13]  Daniel Bausch,et al.  Analysis of Human Peripheral Blood Samples from Fatal and Nonfatal Cases of Ebola (Sudan) Hemorrhagic Fever: Cellular Responses, Virus Load, and Nitric Oxide Levels , 2004, Journal of Virology.

[14]  E. Ramsburg,et al.  Characterization of Nonpathogenic, Live, Viral Vaccine Vectors Inducing Potent Cellular Immune Responses , 2004, Journal of Virology.

[15]  P. Jahrling,et al.  Towards a vaccine against Ebola virus , 2003, Expert review of vaccines.

[16]  P. Jahrling,et al.  Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. , 2003, The American journal of pathology.

[17]  Heinz Feldmann,et al.  Ebola virus: from discovery to vaccine , 2003, Nature Reviews Immunology.

[18]  B. Murphy,et al.  More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved? , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Jahrling,et al.  Evaluation in Nonhuman Primates of Vaccines against Ebola Virus , 2002, Emerging infectious diseases.

[20]  P. Jahrling,et al.  Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses , 2001, Journal of Virology.

[21]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[22]  B. Murphy,et al.  Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. , 2000, Virology.

[23]  G. Weiner,et al.  Uses of granulocyte-macrophage colony-stimulating factor in vaccine development , 2000, Current opinion in hematology.

[24]  S. Hazar,et al.  Filoviridae: Marburg and Ebola viruses. , 2000 .

[25]  E. Nabel,et al.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury , 2000, Nature Medicine.

[26]  B. Murphy,et al.  Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. , 1999, Virology.

[27]  P. Collins,et al.  Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine , 1999, Journal of Virology.

[28]  S. Finke,et al.  Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter , 1999, Journal of Virology.

[29]  B. Murphy,et al.  Recovery of infectious human parainfluenza virus type 3 from cDNA. , 1997, Virology.

[30]  P. Jahrling,et al.  Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. , 1995, International journal of experimental pathology.

[31]  P. Jahrling,et al.  Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates , 1992, Journal of clinical microbiology.

[32]  R. Bronson,et al.  Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system , 1991, Journal of virology.

[33]  R. Tesh,et al.  A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. , 1988, The American journal of tropical medicine and hygiene.

[34]  B. Murphy,et al.  Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans , 1985, Journal of clinical microbiology.

[35]  B. Murphy,et al.  Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. , 1985, Virology.

[36]  B. Murphy,et al.  Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus , 1983, Infection and immunity.

[37]  K. Johnson,et al.  Ebola virus: identification of virion structural proteins. , 1980, The Journal of general virology.

[38]  D. Simpson,et al.  The pathology of experimental Ebola virus infection in monkeys , 1978, The Journal of pathology.

[39]  P Brès,et al.  [The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note]. , 1978, Bulletin of the World Health Organization.